Victory Capital Management Inc Oragenics Inc Transaction History

Victory Capital Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.11 - $15.59 $1,409 - $199,770	12,814 New	12,814 $1,000
Q3 2022 Nov 02, 2022	SELL	$0.23 - $14.18 $436 - $26,927	-1,899 Reduced 12.9%	12,818 $3,000
Q2 2022 Aug 01, 2022	SELL	$0.24 - $0.42 $23 - $41	-99 Reduced 0.67%	14,717 $5,000
Q1 2022 May 04, 2022	SELL	$0.33 - $0.56 $139 - $237	-424 Reduced 2.78%	14,816 $5,000
Q4 2021 Feb 07, 2022	SELL	$0.43 - $0.69 $191 - $307	-446 Reduced 2.84%	15,240 $7,000
Q3 2021 Nov 02, 2021	SELL	$0.58 - $0.84 $413 - $598	-713 Reduced 4.35%	15,686 $10,000
Q2 2021 Aug 03, 2021	BUY	$0.6 - $0.89 $220 - $326	367 Added 2.29%	16,399 $12,000
Q1 2021 May 04, 2021	BUY	$0.52 - $1.52 $1,302 - $3,806	2,504 Added 18.51%	16,032 $15,000
Q4 2020 Feb 01, 2021	BUY	$0.39 - $0.6 $5,275 - $8,116	13,528 New	13,528 $6,000
Q2 2020 Aug 07, 2020	SELL	$0.39 - $0.83 $2,898 - $6,167	-7,431 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$0.43 - $0.75 $72 - $126	-168 Reduced 2.21%	7,431 $4,000
Q4 2019 Feb 04, 2020	SELL	$0.42 - $0.62 $9 - $13	-22 Reduced 0.29%	7,599 $3,000
Q3 2019 Nov 12, 2019	BUY	$0.36 - $0.64 $2,743 - $4,877	7,621 New	7,621 $4,000

Ticker OGEN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 116,395,000
Market Cap $31.4M
Description
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immuni...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.